Top Nucleic Acid Sequencing Startups

Last Updated: November 13, 2021

Business models evolve with time, sometimes due to changes in the market and sometimes due to advent of technology, resulting in emergence of new exciting trends. We at Tracxn closely track the startup ecosystem from across the world and we have come across a whole lot of interesting new themes which are gaining popularity, one of them being Nucleic Acid Sequencing.

Globally there are 149 Nucleic Acid Sequencing companies, and here is the list of the 10 most interesting ones:


Illumina

Manufacturer of DNA sequencing and analyses tools. It is an internet-first brand that provides laboratory instruments and kits & reagents for research & development purposes. Product categories include gene panel & array finder, microarray kits, clinical research & IVD products, and much more.

Company Overview

Location

San Diego (United States)

Investors

Oxford Bioscience Partners, Chevron Technology Ventures, Arch Venture Partners and 19 Other Investors [Investor Details]

Nanopore

Developer of nanopore-based electronic systems for analysis of single molecules. The company’s product is a nanopore-based system that uses DNA sequencing and proprietary electronics to detect and identify the bases in DNA. It also manufactures the necessary reagents and instruments for library preparation, including the VolTRAX microfluidic automated library preparation system. It also developed bespoke software for real-time analysis of data produced by the sequencing systems.

Company Overview

Location

Oxford (United Kingdom)

Investors

GT Healthcare Capital Partners, Anastasia Vlasova, Habib Investments and 83 Other Investors [Investor Details]

Adaptive Biotechnologies engage in immune-based discoveries and diagnostics by combining high-throughput sequencing & bioinformatics to profile immune cell receptor genes. The company’s immune profiling sequencing technology immunoSEQ enables characterization of the immune system, helping scientists & clinicians in research and drug development. The company also offers clonoSEQ for monitoring Minimal Residual Disease (MRD) in blood-based cancers. MRD refers to small numbers of cancer cells that may remain in the patient’s body after treatment and eventually cause cancer recurrence.

Company Overview

Location

Seattle (United States), New York City (United States)

Investors

Tiger Global Management, Microsoft, HTIF and 14 Other Investors [Investor Details]

PacBio

Developer of instrument systems and software for real-time sequencing of single-molecule. It has developed Single-Molecule Real-Time (SMRT) sequencing platform that utilizes the company’s two proprietary technologies Zero-Mode Waveguides (ZMW) and phospholinked nucleotides. The company has developed sequencing and other analytical software that assists with the refining of sequence processing and reports.

Company Overview

Location

Menlo Park (United States)

Investors

Deerfield, Ontario Teachers’ Pension Plan, SoftBank and 21 Other Investors [Investor Details]

GenapSys

GenapSys is a provider of DNA sequencing technologies for applied genomic testing and medical sequencing. It has developed Gene Electronic Nano-Integrated Ultra-Sensitive that is a chip based portable DNA sequencing technologies. The areas of application include Research, Diagnostics, Drug Development, Agriculture, Forensic, and Personal.

Company Overview

Location

Redwood City (United States)

Investors

Farallon Capital Management, Soleus Capital, Foresite Capital and 7 Other Investors [Investor Details]

MedGenome

MedGenome offers end-to-end clinical genomics services for Indian pharma, hospitals, and clinics and genomics bioinformatics to global pharma, research, and diagnostics organizations. It can help physicians and hospitals pinpoint patients’ mutation hotspots, identify prevalent cancer types, flag potential sensitivity to therapies, and link mutations to open clinical trials.

Company Overview

Location

Bangalore (India)

Investors

Tim McLaughlin, Innoven Capital, Emerge Ventures and 22 Other Investors [Investor Details]

Omniome

Omniome provides a genome sequencing platform. The platform can help in cancer diagnostics, higher fidelity for single-cell applications, and enables clinical sequencing in the regions of the genome prone to sequencing errors. The company offers its proprietary technology Sequencing By Binding (SBB) for nucleotide and DNA matching and other clinical sample sequencing.

Company Overview

Location

San Diego (United States)

Investors

Domain Associates, Arch Venture Partners, Decheng Capital and 10 Other Investors [Investor Details]

Phase Genomics

Phase Genomics is commercializing Hi-C sequencing as a way to rapidly perform proximity-guided long range sequencing from organisms where reference genomes are not available. Hi-C is a recently developed technology that allows the extraction of information regarding the physical proximity of DNA stretches inside the nucleus from short- or long-read HT sequencing allowing researchers to reconstruct the 3D organization of DNA within the nucleus. Phase Genomics’ Proximo Hi-C measures the proximity of DNA in vivo and uses that information to scaffold contigs into entire chromosomes, or to deconvolute metagenomes from complex mixtures of environmental DNA.

Company Overview

Location

Seattle (United States)

Investors

Hemi Ventures, Congruent Ventures, Bill & Melinda Gates Foundation and 5 Other Investors [Investor Details]

Developer of a technology for separately sequencing both DNA strand molecules. Its technology claims to have potential applications in a wide range of fields, including oncology, infectious disease, organ transplantation, reproductive and genetic health, and forensics. It also holds an exclusive worldwide license to develop and commercialize Duplex Sequencing which claims to eliminate the false mutations.

Company Overview

Location

Seattle (United States)

Investors

Sahsen, SBIR, Janus Henderson Investors and 6 Other Investors [Investor Details]

Complete Genomics

Complete Genomics is a developer of DNA sequencing platform for human genome sequencing and analysis. It has developed a DNA sequencing platform based on its proprietary DNA nanoball sequencing technology. It is a method of rolling cycle replication to clonally amplify small fragments of DNA into DNA nanoballs which are then attached to a microarray flow cell and sequenced. The sequencing generates fragment lengths of 250-500 bp (mate pair distance), which can then be analyzed using proprietary algorithms. The company’s platform is called the Revolocity Platform and is optimized for the Human whole genome and whole exome sequencing. The company also provides analysis and data management software for generating finished variant reports and assemblies.

Company Overview

Location

San Jose (United States)

Investors

Leader Ventures, Prospect Venture Partners, ATEL Capital Group and 7 Other Investors [Investor Details]


More Startup Collections in Treding Themes


Read more here: Source link